Are we ready for dedicated breast imaging approaches?

Journal of Nuclear Medicine

Volumn 44, Issue 4, 2003, Pages 594-595

  Mankoff, David A ^a,b   Dunnwald, Lisa K ^b   Kinahan, Paul ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; BREAST; BREAST CANCER; BREAST DISEASE; CANCER DIAGNOSIS; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CAUSE OF DEATH; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; ECHOGRAPHY; EXPERIENCE; HEALTH CARE ORGANIZATION; HEART; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; INSTRUMENTATION; LIVER; MAMMOGRAPHY; MOLECULAR BIOLOGY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SAMPLING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOMAMMOGRAPHY; FEMALE; SENSITIVITY AND SPECIFICITY;

DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; ULTRASONOGRAPHY, MAMMARY;

EID: 0037639961     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (22)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Fletcher SW, Black W, Harris R, Rimer BK. Shapiro S Report of the International Workshop on Screening for Breast Cancer J Natl Cancer Inst 1993;85:1644-1656.
3. Flobbe K, Nelemans PJ, Kessels AG, Beets GL, von Meyenfeldt MF, van Engelshoven JM. The role of ultrasonography as an adjunct to mammography in the detection of breast cancer, a systematic review. Eur J Cancer. 2002;38:1044-1050.
4. Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer. 2002;9:141-153.
5. Eubank WB, Mankoff DA. The role of PET in breast cancer: FDG and future directions. Semin Breast Dis. 2002;5:116-127.
6. Taillefer R. Clinical applications of [Tc-99m]-sestamibi scintimammography. Semin Breast Dis. 2002;5:128-141.
7. Khalkahli I, Mena I, Jouanne E. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg. 1994;178:491-497.
8. Kao CH, Wang SJ, Yeh SH. Tc-99m MIBI uptake in breast carcinoma and axillary lymph node metastases. Clin Nucl Med. 1994;19:898-900.
9. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma, initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991;179:765-770.
10. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radioogy. 1993;187:743-750.
11. Palmedo H, Biersack HJ, Lastoria S, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med. 1998;25:375-385.
12. 99mTc-sestamibi breast imaging, multicenter trial results. J Nucl Med. 2000;41:1973-1979.
13. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848-1857.
14. Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad Radiol. 2002;9:773-783.
15. Tornai MP, Bowsher JE, Jaszczak RJ, et al. Mammotomography with pinhole incomplete circular orbit SPECT J Nucl Med 2003;44:583-593.
16. International Commission on Radiation Units and Measurements Medical Imaging. The Assessment of Image Quality ICRU Report No. 54 Bethesda, MD: International Commission on Radiation Units and Measurements; 1996.
17. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J Clin Oncol. 2002;20:379-387.
18. Mankoff DA, Dunnwald LK, Gralow JR, et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow Nucl Med Biol. 2002;29:719-727.
19. Omar WS, Eissa S, Moustafa H, Farag H, Ezzat I, Abdel-Dayem HM Role of thallium-201 chloride and Tc-99m methoxy-isobutyl-isonitrite (sesta-MIBI) in evaluation of breast masses: correlation with the immunohistochemical characteristic parameters (K1-67, PCNA, Bcl, and angiogenesis) in malignant lesions. Anticancer Res. 1997;17:1639-1644.
20. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood now and metabolism in locally advanced breast cancer relationship to response to therapy. J Nucl Med. 2002;43:500-509.
21. Mohno A, Pavarana M, Micciolo R, et al. Comparative study of clinical, pathological and biological characteristics of symptomatic versus asymptomatic breast cancers. Ann Oncol. 2000;11:581-586.
22. 99mTc-MIBI scintimammography in 300 consecutive patients: factors that may affect accuracy. Nucl Med Commun. 1999;20:1113-1121.